Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in type 1 and type 2 diabetic patients

Diabetic Medicine

Volumn 27, Issue 3, 2010, Pages 289-294

  Nybo, M ^a   Poulsen, M K ^a   Grauslund, J ^a   Henriksen, J E ^a   Rasmussen, L M ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biochemical markers; Diabetes; Neuropathy; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; SENSORY NEUROPATHY; BLOOD; COHORT ANALYSIS; DENMARK; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DENMARK; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPROTEGERIN;

EID: 77949377773     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02940.x     Document Type: Article

References (26)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
2. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-20672.
3. Nybo M, Rasmussen LM. Osteoprotegerin released from the vascular wall from vascular smooth muscle cells. Atherosclerosis 2008; 201: 33-35.
4. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 2005; 48: 561-568.
5. Chung AW, Booth AD, Rose C, Thompson CR, Levin A, van BC. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. J Vasc Res 2008; 45: 357-362.
6. Rasmussen LM, Ledet T. Aortic collagen alterations in human diabetes mellitus. Changes in basement membrane collagen content and in the susceptibility of total collagen to cyanogen bromide solubilisation. Diabetologia 1993; 36: 445-453.
7. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrin Metab 2001; 86: 631-637.
8. Ugur-Altun B, Altun A, Gerenli M, Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res Clin Pract 2005; 68: 217-222.
9. Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006; 64: 652-658.
10. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J 2006; 82: 95-100.
11. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94.
12. Grauslund J, Green A, Sjølie AK. Prevalence and 25-year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 2009; 52: 1829-1835.
13. Jeffcoate W. Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? Diabetologia 2004; 47: 1488-1492.
14. Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes 2009; 117: 119-123.
15. Pitocco D, Zelano G, Gioffrè G, Di Stasio E, Zaccardi F, Martini F et al. Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy: a case - control study. Diabetes Care 2009; 32: 1694-1697.
16. Green A, Hauge M, Holm NV, Rasch LL. Epidemiological studies of diabetes mellitus in Denmark. II. A prevalence study based on insulin prescriptions. Diabetologia 1981; 20: 468-470.
17. Sjølie AK. Ocular complications in insulin-treated diabetes mellitus. An epidemiological study. Acta Ophthalmol Suppl 1985; 172: 1-77.
18. Grauslund J, Green A, Sjølie AK. Proliferative retinopathy and proteinuria predict mortality rate in type 1 diabetic patients from Fyn County, Denmark. Diabetologia 2008; 51: 583-588.
19. Sosenko JM, Sparling YH, Hu D, Welty T, Howard BV, Lee E et al. Use of the Semmes-Weinstein monofilament in the Strong Heart Study. Risk factors for clinical neuropathy. Diabetes Care 1999; 22: 1715-1721.
20. Gundersen J. Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe. Acta Chir Scand Suppl 1972; 426: 1-90.
21. Carter SA, Lezack JD. Digital systolic pressures in the lower limb in arterial disease. Circulation 1971; 43: 905-914.
22. Martensson J, Groth S, Rehling M, Gref M. Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med 1998; 39: 2131-2137.
23. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-jB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000; 85: 2355-2363.
24. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39-42.
25. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008; 159: 603-608.
26. Chan BY, Buckley KA, Durham BH, Gallagher JA, Fraser WD. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-jB ligand and osteoprotegerin in plasma and serum. Clin Chem 2003; 49: 2083-2085.